Alnylam Pharmaceuticals, Inc.

Overview

Alnylam Pharmaceuticals, Inc. is a biotechnology company based in the USA, specializing in the development of innovative therapies for genetic diseases. With a workforce of approximately 2,230 employees, the company operates within the Biotech and Pharmaceuticals industry, encompassing pharmaceuticals, healthcare, and life sciences manufacturing. Alnylam’s research efforts are evident in their published document, which includes a research article titled "Outcomes of the HELIOS-B Monotherapy Population: A Post-Hoc Analysis Censoring Data Following Tafamidis Initiation." This document reflects the company's commitment to advancing scientific knowledge and understanding in the field of genetic therapies. The company reported revenue of $2,248 million, indicating a significant presence in the biotechnology sector. Alnylam Pharmaceuticals focuses on leveraging its expertise to address unmet medical needs through its research and development initiatives, contributing to the broader healthcare landscape by providing solutions for patients with rare and complex diseases.

Industry